The addition of bevacizumab to erlotinib improves progression-free survival for patients with advanced NSCLC harbouring activating EGFR and T790M mutation. Results from the BELIEF trial published in Lancet Respiratory Medicine: http://dx.doi.org/10.1016/S2213-2600(17)30129-7